reviewed april 2026|next review october 2026|88 physicians psi has verified|132732 published studies
Pramlintide (Symlin)
Pramlintide is a synthetic amylin analog approved by the FDA as Symlin for use as an adjunct to mealtime insulin in both type 1 and type 2 diabetes. It is the only approved amylin replacement therapy.
Evidence landscape: 132732 published studies
132,732 published items (inflated by broad amylin query). 26 human studies and 151 animal studies indexed for this slug. A clinical evidence base supporting two FDA-approved diabetes indications.
- 26 Human
- 151 Animal
- 23 Reviews
- 132532 Other research
FDA-approved as Symlin (pramlintide acetate) for use alongside mealtime insulin in adults with type 1 or type 2 diabetes who have not achieved adequate glycemic control.
Phase III trials demonstrated HbA1c reduction of 0.3 to 0.5 percentage points and modest weight loss when added to insulin. Over two decades of clinical use.
Replaces amylin, a hormone co-secreted with insulin from healthy beta cells. In type 1 diabetes, amylin production is completely lost. In type 2, it is impaired. No other approved medication replaces this hormone.
PSI Assessment
Insulin replaces one missing hormone in diabetes. Pramlintide replaces a second. Approved as Symlin in 2005, it is a synthetic analog of amylin, a hormone that healthy beta cells release alongside insulin after meals to slow gastric emptying, suppress glucagon, and reduce appetite. In type 1 diabetes, amylin production is lost entirely. In type 2, it is impaired. Pramlintide is the only FDA-approved amylin replacement, and the only approved injectable diabetes medication that works through a non-insulin, non-GLP-1 mechanism.
Insulin replaces one missing hormone. Pramlintide replaces a second. The only FDA-approved amylin replacement therapy.
The mechanism is amylin receptor agonism. Natural amylin is co-secreted with insulin from pancreatic beta cells after meals. It slows gastric emptying, suppresses postprandial glucagon secretion, and promotes satiety through area postrema signaling. Pramlintide is a modified version (with proline substitutions at positions 25, 28, and 29) that prevents the aggregation problem that makes native human amylin unsuitable for injection.
What the evidence supports
FDA-approved for type 1 and type 2 diabetes as an adjunct to mealtime insulin. The only approved amylin replacement therapy. Over two decades of clinical use with a well-characterized safety profile.
What is not yet established
How pramlintide positions alongside GLP-1 agonists in modern diabetes management. Whether the amylin mechanism adds meaningful benefit on top of GLP-1 therapy. Weight management as a primary indication.
Research Evidence
The findings below cover what the clinical program established and how pramlintide positions in the current diabetes landscape.
Evidence by condition
Evidence dimensions across pramlintide's approved indications. Type 1 and type 2 diabetes have deep evidence. Weight management is a secondary observed effect, not a primary indication.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Type 1 Diabetes | ||||
| Type 2 Diabetes | ||||
| Weight Management |
FDA-approved as an adjunct to mealtime insulin in both type 1 and type 2 diabetes. Reduces postprandial glucose excursions and HbA1c by 0.3 to 0.5 percentage points versus placebo.
The HbA1c effect is modest compared to GLP-1 agonists. The clinical value lies in addressing the specific postprandial glucose spikes that insulin alone does not fully control.
Modest weight loss of 1 to 2 kg versus weight gain typically seen with insulin intensification. The only approved diabetes adjunct that produces weight loss through a non-GLP-1 mechanism.
For patients on insulin who are gaining weight, the amylin-mediated satiety effect offers a mechanistically distinct approach to weight neutrality or mild loss.
Hypoglycemia risk increases when pramlintide is combined with insulin, particularly in type 1 diabetes. The prescribing information requires insulin dose reduction at initiation.
This safety consideration is the primary practical limitation. Pramlintide slows gastric emptying, which changes the timing of glucose absorption relative to injected insulin. Careful dose adjustment is essential.
26 Human|151 Animal|23 Reviews
View all 132732 indexed studiesHow Pramlintide (Symlin) Works
Pramlintide is a 37-amino-acid synthetic analog of human amylin with three proline substitutions that prevent the molecular aggregation that makes native amylin unsuitable for pharmaceutical use.
Replaces the amylin hormone that diabetics lose along with insulin. Slows stomach emptying and reduces appetite.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Pramlintide activates amylin receptors (calcitonin receptor complexed with RAMP1/2/3) in the area postrema and hypothalamus. Downstream effects include slowed gastric emptying via vagal signaling, suppression of postprandial glucagon secretion from pancreatic alpha cells, and promotion of satiety. The three proline substitutions (at positions 25, 28, and 29) prevent the beta-sheet aggregation and amyloid fibril formation that characterize native human amylin and are implicated in islet amyloid deposits in type 2 diabetes.
What is Pramlintide (Symlin) being studied for?
Researchers are studying Pramlintide (Symlin) across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Pramlintide (Symlin) overall. This means a compound can have human studies for one condition but only animal data for another.
Type 1 Diabetes
·FDA ApprovedFDA-approved as an adjunct to mealtime insulin. Reduces postprandial glucose excursions. The only non-insulin injectable approved for type 1 diabetes.
Limitations: Hypoglycemia risk requires insulin dose reduction at initiation. Requires a separate injection from insulin. HbA1c effect is modest (0.3-0.5%).
Type 2 Diabetes
·FDA ApprovedFDA-approved as an adjunct to mealtime insulin. Reduces HbA1c and postprandial glucose with modest weight loss versus weight gain on insulin alone.
Limitations: Modest effect size relative to GLP-1 agonists. Requires mealtime injection. Hypoglycemia management is essential.
Weight Management
·Animal StudiesPhase II data in obese subjects without diabetes showed dose-dependent weight loss. The amylin-mediated satiety mechanism is biologically distinct from GLP-1 agonism.
Limitations: Not FDA-approved for weight management. Weight loss is modest (1-2 kg as diabetes adjunct). Phase II only in non-diabetic obesity.
Safety and Regulatory Status
FDA Status: FDA-approved as Symlin (pramlintide acetate) for adjunctive use with mealtime insulin in type 1 and type 2 diabetes.
Prescription status: Prescription-only. Subcutaneous injection before meals. Available through standard pharmacies.
Key safety consideration: Insulin dose reduction required at pramlintide initiation to reduce hypoglycemia risk. This is a labeled requirement, not optional.
Common side effects include nausea (dose-dependent, typically transient during initiation), headache, and anorexia. The primary safety concern is insulin-induced hypoglycemia, which increases when pramlintide is added without appropriate insulin dose reduction.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Pramlintide (Symlin) discussion.
Comparison and Related Research
Pramlintide is most often compared with GLP-1 agonists and other diabetes adjuncts. The comparisons below outline how each differs in mechanism and positioning.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Phase III in type 2 diabetes. Pramlintide as an adjunct to insulin reduced HbA1c and body weight versus placebo over 52 weeks. Basis for the T2D indication.Hollander PA et al., 2003 in Diabetes Care. View on PubMed
- 2.Phase III in type 1 diabetes. Pramlintide reduced HbA1c and postprandial glucose excursions as mealtime adjunct to insulin. Basis for the T1D indication.Whitehouse F et al., 2002 in Diabetes Care. View on PubMed
- 3.Clinical pharmacology review of pramlintide's mechanism, efficacy, and safety across both approved diabetes indications. Summarizes the pivotal trial data.Ryan GJ et al., 2005 in Ann Pharmacother. View on PubMed
- 4.Phase II trial in obese subjects without diabetes. Dose-dependent weight loss over 16 weeks. Early evidence for the weight management potential of amylin agonism.Aronne L et al., 2007 in Obesity. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.